Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

TECX

Tectonic Therapeutic Inc

Nov 27 • 04:00PM ET

49.16

Dollar change +1.33
Percentage change 2.77	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN GILD BIIB BMRN INCY EXEL NBIX RGEN

| Held by: VTI VXF IWC DFAS DFAC DFUS DFAU DCOR WCEO DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.73	Insider Own	47.23%	Shs Outstand	14.75M	Perf Week	11.65%
Market Cap	745.33M	Forward P/E	-	EPS next Y	-5.06	Insider Trans	5.29%	Shs Float	7.79M	Perf Month	19.96%
Income	-45.98M	PEG	-	EPS next Q	-1.36	Inst Own	34.68%	Short Float	5.64%	Perf Quarter	158.74%
Sales	0.00M	P/S	-	EPS this Y	56.25%	Inst Trans	9.36%	Short Ratio	3.59	Perf Half Y	184.49%
Book/sh	10.20	P/B	4.82	EPS next Y	35.83%	ROA	-32.93%	Short Interest	0.44M	Perf Year	230.38%
Cash/sh	10.49	P/C	4.68	EPS next 5Y	-	ROE	-36.32%	52W Range	12.12 - 50.53	Perf YTD	201.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-30.37%	52W High	-2.71%	Beta	1.18
Dividend TTM	-	Quick Ratio	9.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	305.61%	ATR (14)	3.24
Dividend Ex-Date	-	Current Ratio	9.39	EPS Y/Y TTM	-761.03%	Oper. Margin	0.00%	RSI (14)	68.32	Volatility	7.89% 8.04%
Employees	13	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.20	Target Price	72.25
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	79.31%	Payout	0.00%	Rel Volume	0.63	Prev Close	47.83
Sales Surprise	-	EPS Surprise	-42.86%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	122.22K	Price	49.16
SMA20	10.84%	SMA50	32.85%	SMA200	128.37%	Trades		Volume	76,819	Change	2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-24	Initiated	Raymond James	Outperform	$65
Aug-22-24	Initiated	Wells Fargo	Overweight	$55
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13
Jun-27-19	Initiated	Mizuho	Buy	$28
Apr-05-19	Initiated	Janney	Buy
Oct-10-18	Initiated	Guggenheim	Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$47 → $40
Sep-17-18	Initiated	H.C. Wainwright	Buy	$47
Jul-16-18	Initiated	Wells Fargo	Outperform	$40
Jul-16-18	Initiated	Wedbush	Outperform	$38

Show Previous Ratings

Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
04:01PM	Loading…
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
10:50AM	Loading…
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	Loading…
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%
Mar-01-22 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in March (Business Wire)
Feb-21-22 12:14PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Feb-09-22 12:55PM	After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data (Benzinga) -6.25%
07:00AM	AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis (Business Wire)
Feb-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks (Zacks)
Feb-01-22 07:00AM	AVROBIO Announces the Appointment of Sean OBryan as Chief Regulatory Officer (Business Wire)
Jan-28-22 07:00AM	AVROBIO to Present at Cowens 2nd Annual Genetic Medicines Summit (Business Wire) +6.32%
Jan-27-22 07:00AM	AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium 2022 (Business Wire) -5.43%
Jan-25-22 10:00AM	Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now (Zacks)
Jan-07-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks (Zacks)
Jan-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 02:28PM	AvroBio shares plunge after company halts development of Fabry drug (American City Business Journals) -36.63%
09:07AM	Wedbush Says Avrobio Shares Still Undervalued Despite 33% Fall (Investing.com)
07:57AM	Why Avrobio's Shares Are Plunging Today (Benzinga)
07:00AM	AVROBIO Reprioritizes Pipeline Programs (Business Wire)
Dec-07-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.67%
Dec-04-21 06:25AM	Is AVROBIO (NASDAQ:AVRO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-24-21 07:00AM	AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1 (Business Wire)
Nov-09-21 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in November (Business Wire)
Nov-08-21 07:00AM	AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference (Business Wire)
Nov-05-21 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-04-21 07:00AM	AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update (Business Wire)
Nov-03-21 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire) +7.46%
Oct-26-21 07:00AM	AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer (Business Wire)
Oct-20-21 07:00AM	AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit (Business Wire)
Oct-19-21 07:00AM	AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1 (Business Wire)
Oct-06-21 07:00AM	AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress (Business Wire) +5.06%
Oct-05-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SPRINGER TIMOTHY A	Director	Oct 22 '24	Buy	33.59	300,000	10,077,000	4,096,764	Oct 24 05:04 PM
SPRINGER TIMOTHY A	Director	Sep 26 '24	Buy	28.82	50,000	1,440,829	3,796,764	Sep 26 06:15 PM
Leonard Braden Michael	10% Owner	May 13 '24	Buy	1.25	469,753	585,546	4,471,380	May 15 11:21 AM
Leonard Braden Michael	10% Owner	May 14 '24	Buy	1.30	296,882	385,947	4,768,262	May 15 11:21 AM
Golipour Azadeh	Chief Technology Officer	Feb 01 '24	Option Exercise	0.00	37,334	0	68,104	Feb 05 08:01 PM
Ridha Essra	Chief Medical Officer	Feb 01 '24	Option Exercise	0.00	32,834	0	32,834	Feb 05 07:59 PM
Ostrowski Erik	Interim CEO, President and CFO	Feb 01 '24	Option Exercise	0.00	40,084	0	42,384	Feb 05 07:57 PM
Avruch Steven	Chief Legal Officer	Feb 01 '24	Option Exercise	0.00	32,834	0	32,834	Feb 05 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TECX

Tectonic Therapeutic Inc

Upgrade your FINVIZ experience